Back to Home

Generating Clinical, Scientific, And Financial Value In The Field Of Spinal Muscular Atrophy (SMA)

May 8, 2025

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon
View as PDF

Generating Clinical, Scientific, And Financial Value In The Field Of Spinal Muscular Atrophy (SMA)

June 9, 2025

Executive Summary

SMA treatment is rapidly evolving, providing patients with increasing therapeutic options.  However, challenges remain in consistently measuring treatment outcomes and facilitating real-time collaboration among clinicians.  RegenMed Circles offer SMA specialists a platform to collect standardized, compliant real-world data (RWD) from routine clinical practice.  The goal is to generate deeper insights, refine treatment strategies, and ultimately improve outcomes for every individual with SMA.

While potential for data sharing exists, the central aim of RegenMed Circles is to foster clinician-led communities dedicated to accelerating advancements in SMA treatment and promoting clinical excellence.  By participating, clinicians can enhance patient care while benefiting from comprehensive benchmarking tools, peer collaboration, and opportunities for professional development.

Introduction

The spinal muscular atrophy (SMA) treatment landscape has been revolutionized in recent years. From gene therapies and antisense oligonucleotides to small molecule SMN protein enhancers, clinicians now have more therapeutic options available than ever before. However, despite these significant clinical advancements, the infrastructure to systematically collect meaningful, comparative outcome data across these diverse treatments often lags behind.

This limitation hinders the ability of clinicians and researchers to optimize treatment protocols, benchmark effectiveness across different interventions, and contribute robust data to the broader understanding of long-term outcomes in SMA.  RegenMed Circles was established to address this critical need — providing a platform for the SMA community to seamlessly track and analyze patient outcomes at scale.

The Opportunity: Closing The Outcomes Gap

SMA care is increasingly outcome-focused, yet few treatment centers possess real-time, structured insights into their own performance, much less how it compares to others. SMA care teams often face challenges in:

  • Standardize outcome tracking across providers and protocols
  • Analyze trends over time or across treatment types
  • Facilitating knowledge sharing and collaboration on clinical advancements within the SMA community

As individuals with SMA and their families become more informed about outcomes and as payers increasingly require robust data, the necessity for structured, real-world evidence is becoming fundamental — not optional.

We can build your Circle based on your preference of outcomes measurements through the creation of Scoring Formulas, like the ones pictured below, to help you identify treatment outcome trends in SMA.

Regenmed Circles: A Platform For Collaborative Care

RegenMed Circles are secure, collaborative networks that enable clinics to:

  • Collect and structure real-world treatment outcomes with zero workflow disruption
  • Compare anonymized results with national benchmarks
  • Collaborate with peers on protocols, research, and publications
  • Keep full ownership and control of their patient data

Each Circle focuses on a specific treatment domain or outcome type.  Physicians can join existing Circles or propose new ones based on their areas of interest.

Real-world evidence is becoming essential — not optional.

Improving Patient Outcomes Through Real-World Evidence

By collecting outcomes data in a structured, longitudinal format, clinics gain powerful tools to improve care:

  • Identify top-performing protocols and refine treatment plans
  • Enhance cycle prep strategies and optimize timing
  • Share de-identified insights across clinical teams
  • Track long-term patient success — not just short-term metrics

Circle members receive interactive dashboards, cohort-level reports, and access to collaborative datasets.

These tools empower SMA providers to continuously improve outcomes — without hiring new staff or disrupting care delivery.  See below for some examples of what the platform looks like and how it can be used to assess patient outcomes.

Monetizing Your Real-World Data

In addition to improving care, RegenMed Circles create sustainable revenue through compliant, de-identified data licensing.  Clinics can:

  • License aggregate datasets to pharma, device, or digital health partners
  • Earn up to 85% of licensing revenue
  • Participate in studies that shape future treatment development

Revenue is just the beginning.  Circle participation supports scientific publications, conference presentations, and national recognition for clinical leadership.

Call To Action

Circles give doctors treating Spinal Muscular Atrophy a powerful way to elevate care and lead innovation.  Whether you're optimizing supportive care protocols, or working with disease-modifying therapies — Circles make your outcomes work for you.

Join a growing network of physician-led innovators who are shaping the future of SMA care with real-world evidence.

Visit www.rgnmed.com/circles or contact us to learn how to join or launch your own Circle.

CONTACT US

Related white paper: Advancing SMA Care Through Collaborative Data and Real-World Evidence

Related one sheet: Circles For Spinal Muscular Atrophy (SMA)

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Generating Clinical, Scientific, And Financial Value In The Field Of Spinal Muscular Atrophy (SMA)

May 8, 2025

Executive Summary

SMA treatment is rapidly evolving, providing patients with increasing therapeutic options.  However, challenges remain in consistently measuring treatment outcomes and facilitating real-time collaboration among clinicians.  RegenMed Circles offer SMA specialists a platform to collect standardized, compliant real-world data (RWD) from routine clinical practice.  The goal is to generate deeper insights, refine treatment strategies, and ultimately improve outcomes for every individual with SMA.

While potential for data sharing exists, the central aim of RegenMed Circles is to foster clinician-led communities dedicated to accelerating advancements in SMA treatment and promoting clinical excellence.  By participating, clinicians can enhance patient care while benefiting from comprehensive benchmarking tools, peer collaboration, and opportunities for professional development.

Introduction

The spinal muscular atrophy (SMA) treatment landscape has been revolutionized in recent years. From gene therapies and antisense oligonucleotides to small molecule SMN protein enhancers, clinicians now have more therapeutic options available than ever before. However, despite these significant clinical advancements, the infrastructure to systematically collect meaningful, comparative outcome data across these diverse treatments often lags behind.

This limitation hinders the ability of clinicians and researchers to optimize treatment protocols, benchmark effectiveness across different interventions, and contribute robust data to the broader understanding of long-term outcomes in SMA.  RegenMed Circles was established to address this critical need — providing a platform for the SMA community to seamlessly track and analyze patient outcomes at scale.

The Opportunity: Closing The Outcomes Gap

SMA care is increasingly outcome-focused, yet few treatment centers possess real-time, structured insights into their own performance, much less how it compares to others. SMA care teams often face challenges in:

  • Standardize outcome tracking across providers and protocols
  • Analyze trends over time or across treatment types
  • Facilitating knowledge sharing and collaboration on clinical advancements within the SMA community

As individuals with SMA and their families become more informed about outcomes and as payers increasingly require robust data, the necessity for structured, real-world evidence is becoming fundamental — not optional.

We can build your Circle based on your preference of outcomes measurements through the creation of Scoring Formulas, like the ones pictured below, to help you identify treatment outcome trends in SMA.

Regenmed Circles: A Platform For Collaborative Care

RegenMed Circles are secure, collaborative networks that enable clinics to:

  • Collect and structure real-world treatment outcomes with zero workflow disruption
  • Compare anonymized results with national benchmarks
  • Collaborate with peers on protocols, research, and publications
  • Keep full ownership and control of their patient data

Each Circle focuses on a specific treatment domain or outcome type.  Physicians can join existing Circles or propose new ones based on their areas of interest.

Real-world evidence is becoming essential — not optional.

Improving Patient Outcomes Through Real-World Evidence

By collecting outcomes data in a structured, longitudinal format, clinics gain powerful tools to improve care:

  • Identify top-performing protocols and refine treatment plans
  • Enhance cycle prep strategies and optimize timing
  • Share de-identified insights across clinical teams
  • Track long-term patient success — not just short-term metrics

Circle members receive interactive dashboards, cohort-level reports, and access to collaborative datasets.

These tools empower SMA providers to continuously improve outcomes — without hiring new staff or disrupting care delivery.  See below for some examples of what the platform looks like and how it can be used to assess patient outcomes.

Monetizing Your Real-World Data

In addition to improving care, RegenMed Circles create sustainable revenue through compliant, de-identified data licensing.  Clinics can:

  • License aggregate datasets to pharma, device, or digital health partners
  • Earn up to 85% of licensing revenue
  • Participate in studies that shape future treatment development

Revenue is just the beginning.  Circle participation supports scientific publications, conference presentations, and national recognition for clinical leadership.

Call To Action

Circles give doctors treating Spinal Muscular Atrophy a powerful way to elevate care and lead innovation.  Whether you're optimizing supportive care protocols, or working with disease-modifying therapies — Circles make your outcomes work for you.

Join a growing network of physician-led innovators who are shaping the future of SMA care with real-world evidence.

Visit www.rgnmed.com/circles or contact us to learn how to join or launch your own Circle.

CONTACT US

Related white paper: Advancing SMA Care Through Collaborative Data and Real-World Evidence

Related one sheet: Circles For Spinal Muscular Atrophy (SMA)

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Read The Latest

June 26, 2025

Invest in the Future: Webinar with Our CEO and Co-Founder

Discover the incredible growth potential of our company! Join our CEO and Co-Founder for insights into our $100B market opportunity, ongoing market traction, and future projections.

June 4, 2025

Advantages Of Circles Over "Big Data" RWE

Discover how Circles transform Big Data RWE by providing transparent, high-integrity insights directly from trusted sources. Say goodbye to fragmented, costly data and unlock meaningful, clinically relevant information while empowering physicians.

June 3, 2025

Peptides In Modern Medicine: Establishing Safety and Efficacy

Peptides are revolutionizing clinical diagnosis and treatment with their high selectivity and favorable side effect profiles. Here are some key insights:

RegenMed LLC Logo
Scroll Up Arrow

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

Forward looking statements were included here that the Company believes to be accurate given the current information. They involve known and unknown risks, uncertainties and other important factors which if changed may affect the outcome(s).

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242., is the Intermediary for this offering and is not an affiliate of or connected with the Issuer.  Please check our background on FINRA's BrokerCheck.
DealMaker Securities LLC does not make investment recommendations.
DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.
DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment.
DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.
DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

Copyright © 2025. RegenMed, Inc. All rights reserved.